From the Department of Emergency and Intensive Care, ASST Monza, Monza, Italy.
School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
ASAIO J. 2023 Aug 1;69(8):e376-e383. doi: 10.1097/MAT.0000000000001997. Epub 2023 Jul 29.
Extracorporeal membrane oxygenation (ECMO) has been used in highly selected COVID-19 patients with severe respiratory failure. Scarce data exist on long-term outcomes of these patients. We performed a single-center prospective evaluation of consecutive COVID-19 ECMO patients successfully discharged from the intensive care unit between February 2020 and January 2022. Physical, cognitive and psychological outcome was assessed at 3, 6, and 12 months by in-person evaluation. All the 34 discharged patients (median age 49 years old) were alive at one year, and 25 of them were evaluated at the follow-up clinic. 67% of patients had muscle weakness, with improvement over time (p = 0.032). The percentage of patients able to return to work progressively increased, up to 86% at 1 year. 23% of patients experienced fatigue. Participation restriction improved over time for both physical (p = 0.050) and emotional (p = 0.005) problems. Cognitive impairment, anxiety, and depression occurred in 29%, 29%, and 23% of patients, respectively, with no changes over time. Health-related quality of life was good. In conclusion, COVID-19 ECMO patients suffer from significant long-term sequelae. However, multidimensional outcomes continued to improve over the follow-up time.
体外膜肺氧合 (ECMO) 已在患有严重呼吸衰竭的 COVID-19 高度选择患者中使用。关于这些患者的长期结果的数据很少。我们对 2020 年 2 月至 2022 年 1 月期间从重症监护病房成功出院的连续 COVID-19 ECMO 患者进行了单中心前瞻性评估。通过亲自评估在 3、6 和 12 个月时评估身体、认知和心理结果。所有 34 名出院患者(中位年龄 49 岁)在一年时均存活,其中 25 名在随访诊所接受了评估。67%的患者存在肌肉无力,且随时间推移逐渐改善(p=0.032)。能够重返工作岗位的患者比例逐渐增加,一年时达到 86%。23%的患者经历疲劳。身体(p=0.050)和情绪(p=0.005)问题的参与受限随时间推移而改善。29%、29%和 23%的患者分别出现认知障碍、焦虑和抑郁,且随时间无变化。健康相关生活质量良好。总之,COVID-19 ECMO 患者存在显著的长期后遗症。然而,多维结局在随访期间持续改善。